PRL-3 promotes breast cancer progression by downregulating p14ARF-mediated p53 expression

Xie,Hua; Wang,Hao

doi:10.3892/ol.2017.7639

PRL-3 promotes breast cancer progression by downregulating p14ARF-mediated p53 expression

Authors:
- Hua Xie
- Hao Wang
View Affiliations

Affiliations: Department of Thoracic Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P.R. China, Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P.R. China
Published online on: December 19, 2017 https://doi.org/10.3892/ol.2017.7639
Pages: 2795-2800
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prior studies have demonstrated that phosphatase of regenerating liver-3 (PRL-3) serves avital function in cell proliferation and metastasis in breast cancer. However, the molecular mechanisms underlying the function of PRL‑3 in breast cancer remain unknown. PRL‑3 expression was analyzed in 24 pairs of breast cancer and normal tissues using the reverse transcription‑quantitative polymerase chain reaction assay. The results of the present study identified that the expression of PLR‑3 in breast cancer tissues was increased 4.2‑fold, compared with normal tissues. Notably, overexpression of PRL‑3 significantly promoted the proliferation of cancer cells and inhibited endogenous p53 expression by downregulating the expression level of p14 alternate reading frame (p14ARF). In addition, decreased expression levels of PRL‑3 resulted in decreased breast cancer cell proliferation and increased expression level of p14ARF. These results suggested that PRL‑3 enhances cell proliferation by downregulating p14ARF expression, which results in decreased levels ofp53. The results of the present study demonstrated that PRL‑3 promotes tumor proliferation by affecting the p14ARF‑p53 axis, and that it may serve as a prognostic marker for patients with breast cancer.

View Figures

View References

1	McGuire A, Brown JA, Malone C, McLaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers (Basel). 7:908–929. 2015. View Article : Google Scholar : PubMed/NCBI
2	Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM and Baade PD: The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 36:237–248. 2012. View Article : Google Scholar : PubMed/NCBI
3	Zhou J, Cheong LL, Liu SC, Chong PS, Mahara S, Bi C, Ong KO, Zeng Q and Chng WJ: The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. Mol Cancer. 11:722012. View Article : Google Scholar : PubMed/NCBI
4	Stephens BJ, Han H, Gokhale V and Von Hoff DD: PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther. 4:1653–1661. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kato H, Semba S, Miskad UA, Seo Y, Kasuga M and Yokozaki H: High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: A predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res. 10:7318–7328. 2004. View Article : Google Scholar : PubMed/NCBI
6	Mollevi DG, Aytes A, Padullés L, Martínez-Iniesta M, Baixeras N, Salazar R, Ramos E, Figueras J, Capella G and Villanueva A: PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer. 99:1718–1725. 2008. View Article : Google Scholar : PubMed/NCBI
7	Miskad UA, Semba S, Kato H and Yokozaki H: Expression of PRL-3 phosphatase in human gastric carcinomas: Close correlation with invasion and metastasis. Pathobiology. 71:176–184. 2004. View Article : Google Scholar : PubMed/NCBI
8	Wang Z, Cai SR, He YL, Zhan WH, Zhang CH, Wu H, Peng JJ, Xu JB, Zhang XH, Wang L and Song W: Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients. J Cancer Res Clin Oncol. 135:1041–1046. 2009. View Article : Google Scholar : PubMed/NCBI
9	Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, Bardelli A and Broggini M: PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res. 11:6835–6839. 2005. View Article : Google Scholar : PubMed/NCBI
10	Liu H, Al-aidaroos AQ, Wang H, Guo K, Li J, Zhang HF and Zeng Q: PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells. BMC Cancer. 13:802013. View Article : Google Scholar : PubMed/NCBI
11	Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, et al: Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 111:806–815. 2008. View Article : Google Scholar : PubMed/NCBI
12	Ma Y and Li B: Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix. Med Oncol. 28:775–780. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wang L, Peng L, Dong B, Kong L, Meng L, Yan L, Xie Y and Shou C: Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol. 17:1517–1522. 2006. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Ustaalioglu BB, Bilici A, Barisik NO, Aliustaoglu M, Vardar FA, Yilmaz BE, Seker M and Gumus M: Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer. Clin Transl Oncol. 14:911–922. 2012. View Article : Google Scholar : PubMed/NCBI
16	Min L, Ma RL, Yuan H, Liu CY, Dong B, Zhang C, Zeng Y, Wang L, Guo JP, Qu LK and Shou CC: Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients. Asian Pac J Cancer Prev. 16:2819–2826. 2015. View Article : Google Scholar : PubMed/NCBI
17	Sherr CJ: Principles of tumor suppression. Cell. 116:235–246. 2004. View Article : Google Scholar : PubMed/NCBI
18	Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, et al: Corrigendum: Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol. 17:13702015. View Article : Google Scholar : PubMed/NCBI
19	Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, et al: Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2 and p53 status. BMC Cancer. 13:2252013. View Article : Google Scholar : PubMed/NCBI
20	Milojkovic A, Hemmati PG, Müer A, Overkamp T, Chumduri C, Jänicke RU, Gillissen B and Daniel PT: p14ARF induces apoptosis via an entirely caspase-3-dependent mitochondrial amplification loop. Int J Cancer. 133:2551–2562. 2013.PubMed/NCBI
21	Silva J, Dominguez G, Silva JM, García JM, Gallego I, Corbacho C, Provencio M, España P and Bonilla F: Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene. 20:4586–4590. 2001. View Article : Google Scholar : PubMed/NCBI
22	Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC and Inoue K: Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene. 32:4120–4129. 2013. View Article : Google Scholar : PubMed/NCBI
23	Wazir U, Jiang WG, Yasaei H, Linne H, Newbold RF and Mokbel K: P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer. Anticancer Res. 33:2185–2189. 2013.PubMed/NCBI
24	Xia L, Paik A and Li JJ: p53 activation in chronic radiation-treated breast cancer cells: Regulation of MDM2/p14ARF. Cancer Res. 64:221–228. 2004. View Article : Google Scholar : PubMed/NCBI
25	Wei J, Noto JM, Zaika E, Romero-Gallo J, Piazuelo MB, Schneider B, El-Rifai W, Correa P, Peek RM and Zaika AI: Bacterial CagA protein induces degradation of p53 protein in a p14ARF-dependent manner. Gut. 64:1040–1048. 2015. View Article : Google Scholar : PubMed/NCBI
26	Wang J, Ding S, Duan Z, Xie Q, Zhang T, Zhang X, Wang Y, Chen X, Zhuang H and Lu F: Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression. Oncogene. 35:1692–1702. 2016. View Article : Google Scholar : PubMed/NCBI
27	Lv H, Liu R, Fu J, Yang Q, Shi J, Chen P, Ji M, Shi B and Hou P: Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway. Cell Cycle. 13:2962–2974. 2014. View Article : Google Scholar : PubMed/NCBI